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Abstract
Introduction: T cell immunoglobulin and mucin domain-2 (TIM-2) has been shown to regulate CD4 T cell
activation. However, the role of TIM-2 in the autoimmune disease models has not been clarified yet. In this study,
we investigated the effects of anti-TIM-2 monoclonal antibodies (mAbs) in collagen-induced arthritis (CIA) to
determine whether TIM-2 contributes to the development of T helper (Th) 1 or Th17 cells and joint inflammation.
Methods: DBA/1 mice were treated with anti-TIM-2 mAbs during the early or late phase of CIA. Type II collagen
(CII)-specific CD4 T-cell proliferative response and cytokine production were assessed from lymph node cell culture.
The serum levels of CII-specific antibody were measured by ELISA. The expression of TIM-2 on CD4 T cells or B cells
was determined by flow cytometric analysis.
Results: Administration of anti-TIM-2 mAbs in early phase, but not late phase, significantly exacerbated the
development of CIA. Although anti-TIM-2 mAbs treatment did not affect the development of Th1 or Th17 cells in
the draining lymph node, the serum levels of anti-CII antibodies were significantly increased in the anti-TIM-2-
treated mice. TIM-2 expression was found on splenic B cells and further up-regulated by anti-immunoglobulin (Ig)
M, anti-CD40, and interleukin(IL)-4 stimulation. In contrast, CD4 T cells did not express TIM-2 even when stimulated
with both anti-CD3 and anti-CD28 mAbs. Interestingly, anti-TIM-2 mAbs enhanced proliferation and antibody
production of activated B cells in vitro.
Conclusions: TIM-2 signaling influences both proliferation and antibody production of B cells during the early
phase of CIA, but not induction of Th1 or Th17 cells.
Introduction
The T cell immunoglobulin and mucin domain (TIM)
family has recently been implicated in the regulation of
T cell activation and immune responses [1,2]. The genes
of this family were found within the Tapr (T cell and air-
way phenotype regulator) locus on mouse chromosome
11B1.1, which is syntenic to human chromosome 5q33.2,
a region that has been linked to allergic diseases [3]. To
date, four proteins (TIM-1, -2, -3, and -4) have been
identified in mice and three proteins (TIM-1, -3, and -4)
have been found in humans [2]. In the mouse, TIM-1
and TIM-3 have polymorphism at the protein level,
represented by BALB/c-type and B6-type [3]. No human
orthologue for mouse TIM-2 has been identified
although, given its close sequence homology, TIM-1 may
share some of its functions [1-5]. All proteins are type I
transmembrane proteins with common structural motifs
including extracellular IgV and mucin domains, and
intracellular domains. TIM-1, TIM-2, and TIM-3, but
not TIM-4, contain a conserved intracellular tyrosine
phosphorylation motif that is involved in transmembrane
signaling [2,3].
TIM-2 was also identified as a ligand for semaphoring
4A (Sema4A), which was expressed on activated macro-
phages, B cells, and dendritic cells [6]. Further study has
identified another ligand for TIM-2, the heavy chain of
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binding protein, which is composed of heavy and light
chain subunits [7]. Expression of TIM-2 has been found
on B cells, epithelial cells in the liver and kidney, and
oligodendrocytes, although the function of TIM-2 in
these cells has not yet been understood [4,8]. It has also
been reported that TIM-2 is preferentially expressed on
T helper (Th) 2 cells [9,10]. Some studies support roles
for TIM-2 as a negative regulator of Th2 immune
responses [5,9,10]. Initial studies showed that soluble
TIM-2-Ig fusion protein induced T cell hyperprolifera-
tion and enhanced production of Th2 cytokines in vivo
[9]. A subsequent study also showed that TIM-2-Ig
treatment exacerbated lung inflammation in the ovalbu-
min (OVA)-induced asthma model [10]. Eosinophil
numbers were increased in bronchial lavage, lymph
node (LN) cell proliferation in response to OVA was
increased, and production of Th2-type cytokines was
heightened. Moreover, TIM-2-deficient mice showed an
exacerbated lung inflammation in the OVA-induced
asthma model [10]. Thus, these findings have suggested
that TIM-2 is a critical negative regulator of Th2
immune responses. However, the immunological func-
tion of TIM-2 under Th1-polarizing conditions has not
been investigated extensively. Here, we have examined
the function of TIM-2 in the development of collagen-
induced arthritis (CIA), which is a Th1-mediated auto-
immune disease model, by administering a newly gener-
ated anti-TIM-2 monoclonal antibodies (mAbs). Our
present results suggest that TIM-2 signaling influences
both proliferation and antibody production of B cells
during the early phase of CIA, but not induction of Th1
or Th17 cells.
Materials and methods
Animals and cells
Male DBA/1 mice and female Sprague Dawley rats were
purchased from Charles River Laboratories (Kanagawa,
Japan). FcRg-deficient mice were supplied by Y. Suzuki
(Department of Nephrology, Juntendo University, Tokyo,
Japan) [11,12]. All mice were 7 to 10 weeks old at the
start of experiments and kept under specific pathogen-
free conditions during the experiments. All animal
experiments were approved by Juntendo University Ani-
mal Experimental Ethics Committee. A cDNA fragment
encoding the entire open reading frame of mouse TIM-2
molecule was prepared by RT-PCR from Con A-activated
splenocytes of C57BL/6 mouse. The PCR product was
cloned into pMKITneo vector and transfected into NRK-
52E (normal rat kidney) or L5178Y (murine T lym-
phoma) cells by electroporation (TIM-2/NRK or TIM-2/
L5178Y). Stable NRK-52E cells expressing TIM-1-BALB,
TIM-1-B6, TIM-3-BALB, TIM-3-B6, or TIM-4 were also
established in our laboratory by similar methods. These
cells were cultured in RPMI1640 medium containing
10% FCS, 10 mM HEPES, 2 mM L-glutamine, 0.1 mg/ml
penicillin and streptomycin, and 50 μM 2-ME.
Generation of anti-mouse TIM-2 mAbs
The anti-mouse TIM-2 mAbs were generated by immu-
nizing Sprague Dawley rats with TIM-2-Ig, consisting of
the extracellular domain (aa 1-230 of mouse TIM-2) [3]
and the Fc portion of mouse IgG2a, emulsified in com-
plete Freund’s adjuvant (CFA: Difco Laboratories,
Detroit, MI, USA). Three days after the final immuniza-
tion, LN cells were fused with P3U1 myeloma cells.
After hypoxanthine-aminopterin-thymidine selection,
hybridomas producing anti-TIM-2 mAb (RMT2-14, rat
IgG2a/l; RMT2-25, rat IgG2a/; and RMT2-26, rat
IgG2b/) were selected by their reactivity to mouse
TIM-2-transfected cells, but not to parental cells, by
flow cytometry and then cloned by limiting dilution.
The mAbs were purified from ascites of SCID mice by
the octanoic acid and ammonium sulfate precipitation
method, and purity was verified by SDS-PAGE analysis.
Anti-TIM-1 (RMT1-17), anti-TIM-3 (RMT3-23), and
anti-TIM-4 (RMT4-53) mAbs were also generated pre-
viously [13,14].
Induction of CIA, mAb treatment, and clinical assessment
of arthritis
DBA/1 mice (10 mice per group) were immunized intra-
dermally at the base of the tail with 200 μg of bovine type
II collagen (CII; Collagen Research Center, Tokyo, Japan)
in 0.05 M acetic acid, emulsified in CFA. Twenty-one
days after primary immunization, some groups of mice
were boosted in the same way with 200 μg of CII in 0.05
M acetic acid, emulsified in incomplete Freund’s adjuvant
(IFA). The immunized mice were randomly selected and
intraperitoneally administered with 300 μg of anti-TIM-2
mAbs or control rat IgG (Sigma-Aldrich, St Louis, MO,
USA) every three days from day 0 to day 42, or day 0, 2,
5, 8, 11, 14, and 17 for the early phase, or day 15, 17, 20,
23, 26, 29, and 32 for the late phase. Mice were moni-
tored for arthritis every day and scored in a blinded man-
ner. The swelling of four paws was graded from 0 to 4 as
follows: grade 0, no swelling; grade 1, one inflamed digit;
grade 2, two inflamed digits; grade 3, more than one digit
and footpad inflamed; and grade 4, all digits and footpad
inflamed. Each paw was graded, and the four scores were
totaled so that the maximal score per mouse was 16. Inci-
dence was expressed as the percentage of mice that
showed paw swelling in the total number of mice
examined.
Histological analysis
CIA mice were killed at day 45. The hind limbs were
removed and fixed in buffered formalin, decalcified in
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paraffin, sectioned, and stained with H&E.
T cell stimulation in vitro
Draining LN cells from 10 mice were isolated and pooled
in each group, and triplicate cultured in 96-well flat-bot-
tom microculture plates at a density of 6 × 10
5 cells/well
in the presence or absence of the indicated doses of
denatured CII (dCII: 60°C, 30 minutes). In another
experiment, DBA/1 mice (5 mice per group) were immu-
nized subcutaneously with 5 μgo fO V Aw i t hC F Aa n d
intraperitoneally administrated with 300 μg of RMT2-14
or control rat IgG on days 0, 2, and 4. On day 7, LN cells
(6 × 10
5 cells/well) from five mice were pooled in each
group and restimulated with the indicated doses of OVA
in 96-well plates. All cultures were pulsed with
3H-thymi-
dine (0.5 μCi/well; PerkinElmer, Waltham, MA, USA) for
the last six hours of a 72-hour or 96-hour culture and
harvested on a Micro 96 Harvester (Molecular Devices,
Sunnyvale, CA USA). Incorporated radioactivity was
measured on a microplate beta counter (Micro b Plus;
PerkinElmer, Waltham, MA, USA). To determine the
production of cytokines, cell-free supernatants were col-
lected from each well at 72 hours or 120 hours and
assayed for IFN-g or IL-17 using Mouse IFN-g or IL-17
ELISA Ready-SET-Go! kit (eBioscience, San Diego, CA,
USA) according to the manufacturer’s instructions.
Preparation of activated CD4 and B cells
CD4 T cells were purified from the spleen of DBA/1
mice by passing it through a nylon wool column (Wako
Pure Chemical Industries, Osaka, Japan) and by using
an auto-MACS columns with CD4 T cell isolation kit
(Miltenyi Biotec, Bergisch Gladbach, Germany) accord-
ing to the manufacturer’s instructions. Purified CD4
T cells were stimulated with immobilized anti-CD3
mAb (5 μg/ml) in the presence or absence of anti-CD28
mAb (5 μg/ml). B cells were also purified by using the
auto-MACS column with B cell isolation kit. Purified B
cells were stimulated with anti-IgM antibody (Ab)
(5 μg/ml), anti-CD40 mAb (5 μg/ml) and/or recombi-
nant mouse IL-4 (20 ng/ml) for 48 hours. The anti-CD3
(145-2C11), anti-CD40 (HM40-3), and recombinant
mouse IL-4 were purchased from eBioscience (San
Diego, CA, USA). Goat anti-mouse IgM F(ab’)2 Ab was
purchased from Jackson ImmunoResearch Laboratories
( W e s tG r o v e ,P A ,U S A ) .A n t i - C D 2 8( P V - 1 )m A bw a s
kindly provided by Dr. R. Abe (Tokyo University of
Science, Chiba, Japan) and Dr. C. June (University of
Pennsylvania, Philadelphia, PA, USA).
Flow cytometric analysis
Cells (0.5 to 1 × 10
6) were first preincubated with unla-
beled anti-CD16/32 mAb to avoid non-specific binding
of Abs to FcgR and then incubated with biotinylated
mAbs. After washing with PBS twice, the cells were
incubated with PE-labeled streptavidin. After washing
with PBS twice, the stained cells (live-gated on the basis
of forward and side scatter profiles and propidium
iodide exclusion) were analyzed on a FACSCalibur (BD
Biosciences, San Jose, CA, USA), and data were pro-
cessed using the CellQuest program (BD Biosciences,
San Jose, CA, USA). Purified anti-CD16/32 (2.4G2) was
purchased from BD Biosciences (San Jose, CA, USA).
FITC-conjugated anti-CD3 (145-2C11) and CD19
(MB19-1), allophycocyanin-conjugated anti-CD4 (RM4-
5) and CD45R/B220 (RA3-6B2), rat IgG isotype control,
and PE-labeled streptavidin were purchased from
eBioscience (San Diego, CA, USA).
Serum anti-CII antibody levels
Sera were collected from each mouse on day 16, 24, or
32 and the titers of anti-CII IgG Abs were measured by
ELISA. Bovine CII (1 μg/ml) was coated onto 96-well
ELISA plates overnight at 4°C. After blocking with 1%
BSA in PBS, serially diluted serum samples were added
and incubated for one hour at room temperature. After
washing, biotin-conjugated rat anti-mouse IgG1, IgG2a,
or IgG2b mAbs (BD Biosciences, San Jose, CA, USA)
were added and incubated for one hour at 37°C, washed,
and then developed with Vectastain ABC kit (Vector
Laboratories, Burlingame, CA, USA) and o-phenylendia-
mine (Wako Pure Chemical Industries, Osaka, Japan).
After terminating the reaction with 2N H2SO4,O Da t
490/595 nm was measured on a microplate reader (Bio-
Rad, Hercules, CA, USA). A standard serum composed
of a mixture of sera from arthritic mice was added to
each plate in serial dilutions and a standard curve was
constructed. The standard serum was defined as one
unit and the antibody titers of serum samples were
determined by the standard curve.
In vitro B cell proliferation and Ig production assays
Purified B cells (1 × 10
5/well) from DBA/1, BALB/c, or
FcRg-deficient mice were triplicate cultured with anti-
IgM Ab (5 μg/ml), anti-CD40 mAb (5 μg/ml), and/or
recombinant mouse IL-4 (20 ng/ml) in the absence or
presence of human H-ferritin (EMD Chemicals, Gibbs-
town, HJ, USA) in 96-well flat-bottomed plates. Anti-
CD16/32 mAb (5 μg/ml) and 10 μg/ml of anti-TIM-2
mAbs or control rat IgG were also added at the start of
culture. To assess proliferative responses, the cultures
were pulsed with
3H-thymidine (0.5 μCi/well) for the
last six hours of a 72-hour culture and harvested. Incor-
porated radioactivity was measured as described above.
For analysis of Ig secretion, 50 μl of day 7 culture super-
natants were subjected to the cytometric bead array
(CBA) using Mouse Immunoglobulin Isotyping Kit (BD
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facturer’s instructions. This kit is highly sensitive and
useful for a qualitative assay, but not a quantitative
assay.
Statistical analysis
Statistical analyses for parametric data were performed
by unpaired Student’s t-test. Nonparametric data were
analyzed by the Mann-Whitney U test. Incidence was
analyzed by Logrank test. The results are expressed as
the mean ± standard error of the mean. Values of P <
0.05 were considered significant.
Results
Establishment of anti-mouse TIM-2 mAbs
We immunized Sprague Dawley rats with TIM-2-Ig chi-
mera protein and screened the hybridomas producing
mAb that reacted with TIM-2 transfectants but not paren-
tal cells. Three mAbs, designated RMT2-14, RMT2-25,
and RMT2-26 were selected. As shown in Figure 1a, all
these mAbs reacted with TIM-2/NRK cells but not with
parental NRK or the other TIM family-transfected (TIM-1
B6/NRK, TIM-1 BALB/NRK, TIM-3 B6/NRK, TIM-3
BALB/NRK, and TIM-4/NRK) cells. To characterize the
antigen recognized by these mAbs, cell lysates of TIM-2/
L5178Y or L5178Y cells were immunoprecipitated with
these mAbs. Then the precipitates were analyzed by SDS-
PAGE under nonreducing conditions and immunoblotting
with biotin-conjugated RMT2-14, RMT2-25, or RMT2-26.
All three mAbs precipitated an approximately 55 kDa pro-
tein from TIM-2/L5178Y cells, but not from L5178Y cells,
consistent with the molecular mass of TIM-2 previously
reported [6] [See Additional file 1]. To further determine
whether these mAbs bind to the same epitope in the TIM-
2 molecule, TIM-2/L5178Y cells were pre-incubated with
unlabeled mAbs as a competitor to block the binding of
biotinylated mAbs [See Additional file 2]. The binding of
biotin-RMT2-14 was blocked by RMT2-14 and RMT2-25,
but not by RMT2-26. In contrast, the binding of biotin-
RMT2-25 or biotin-RMT2-26 was blocked by RMT2-25
and RMT2-26, but not by RMT2-14. These results indi-
cated that three mAbs bound to related but different epi-
topes in the TIM-2 molecule.
A previous report showed that TIM-2 bound to
Sema4A [6]. Thus, we generated Sema4A-Ig fusion pro-
tein and Sema4A-transfected cells, and examined the
binding to TIM-2. However, we could not confirm the
binding of Sema4A-Ig to TIM-2-transfected cells or the
binding of TIM-2-Ig to Sema4A-transfected cells by
flow cytometry (data not shown). Another report
revealed that TIM-2 bound to H-ferritin [4]. To exam-
ine whether H-ferritin can bind to TIM-2/NRK cells, we
prepared an Alexa647-labeled human recombinant
H-ferritin. As shown in Figure 1b, Alexa647-labeled
H-ferritin bound to TIM-2/NRK cells, but not to paren-
tal NRK or the other TIM family-transfected NRK cells.
Moreover, preincubation with our anti-TIM-2 mAbs
blocked the H-ferritin binding to TIM-2/L5178Y cells
(Figure 1c). RMT2-25 and RMT2-26 showed somewhat
stronger blocking activities than RMT2-14.
Anti-TIM-2 mAb treatment exacerbates CIA
To explore the contribution of TIM-2 to the develop-
ment of autoimmune arthritis, we first administrated
anti-TIM-2 mAb (RMT2-14) or control IgG from day 0
to day 42 into the CIA mice. DBA/1 mice were immu-
nized with CII/CFA on day 0 and with CII/IFA on day
21. As shown in Figure 2a, clinical score of arthritis was
assessed from the day 0. When mice were treated with
RMT2-14, clinical score was significantly more severe
than the control IgG-treated mice (P <0 . 0 5o nd a y2 8
to 37 and day 44 to 45). Additionally, the incidence of
disease was higher in the RMT2-14-treated group than
control IgG-treated group (Figure 2b, P = 0.183). Histo-
logical analysis of the joints also showed more severe
arthritis in the RMT2-14-treated mice compared with
the control IgG-treated mice (Figure 3). The hind paw
sections from RMT-2-14-treated mice showed more
extensive infiltration of mononuclear cells, synovial
hyperplasia, pannus formation, and cartilage destruction
as compared with the control IgG-treated mice. These
results suggested a substantial contribution of TIM-2 to
the pathogenesis of CIA.
Effect of anti-TIM-2 mAbs during early or late phase of CIA
We next examined the effect of anti-TIM-2 mAbs during
the early phase or the late phase of CIA. Mice were immu-
nized with CII/CFA only once on day 0 and treated with
anti-TIM-2 mAbs (RMT2-14, RMT2-25, or RMT2-26) or
control IgG from day 0 to day 17 for the early phase or
from day 15 to day 32 for the late phase. In the early
phase, administration of RMT2-14 (P < 0.05 on day 17 to
27 and day 37 to 39) and RMT2-25 (P < 0.05 on day 32 to
39) significantly enhanced the development of CIA as
compared with control IgG (Figure 2c). In contrast,
administration of RMT2-26 did not affect the develop-
ment of CIA (Figure 2c). In the late phase, administration
of RMT2-14, RMT2-25, or RMT2-26 did not affect the
disease severity (Figure 2d). These results indicate that the
exacerbation of arthritis by RMT2-14 and RMT2-25 is
implicated in the early phase of CIA development.
Effect of anti-TIM-2 mAb treatment on the development
of antigen-specific T cells
The exacerbation of arthritis by anti-TIM-2 mAbs might
result from modulation of CII-specific CD4 T cell
responses. To address this possibility, DBA/1 mice were
immunized with CII/CFA on day 0 and CII/IFA on day
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control IgG from day 0 to day 42. Draining LN cells
were isolated at day 45, and proliferative response and
Th1 and Th17 cytokine production (IFN-g and IL-17)
against dCII were assessed. As shown in Figure 4a,
dCII-specific proliferative response and production of
IFN-g and IL-17 were almost comparable between the
anti-TIM-2 mAb-treated mice and the control IgG-trea-
ted mice (P>0.05 at every concentration of dCII
amongst every group). IL-4 and IL-5 were also measured
but not detectable in the culture supernatants (data not
shown).
To further evaluate the effect of anti-TIM-2 mAb on
the early phase of CII-specific Th1 and Th17 cells, DBA/
1 mice were immunized with CII/CFA on day 0 and trea-
ted with RMT2-14 or control IgG every three days from
day 0 to day 12. LN cells were isolated at day 14, and pro-
liferative response and cytokine production against dCII
were assessed [See Additional file 3]. However, both pro-
liferative response and cytokine production (IFN-g and
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Figure 1 Characterization of anti-TIM-2 mAbs. (a) Reactivity of anti-T cell immunoglobulin and mucin domain (TIM)-2 monoclonal antibodies
(mAbs) to mouse TIM family molecules. NRK-52E-derived TIM transfectants and parental cells were stained with biotinylated RMT2-14, RMT2-25,
RMT2-26, specific mAbs against each TIM family molecule, or control IgG followed by PE-labeled streptavidin. Thick lines indicate the staining
with the respective mAb and the dotted lines indicate background staining with control IgG. (b) H-ferritin binds to TIM-2 transfectant. NRK-52E-
derived TIM transfectants were stained with Alexa647-labeled H-ferritin. Thick lines indicate the staining with the H-ferritin and the dotted lines
indicate background staining with PBS. (c) Anti-TIM-2 mAbs inhibit H-ferritin binding to TIM-2 transfectant. TIM-2/L5178Y cells were pretreated
with the indicated anti-TIM-2 mAb (thick lines) or control IgG (solid lines) and then stained with Alexa647-labeled H-ferritin. The dotted lines
indicate background staining with PBS.
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Figure 2 Effect of anti-TIM-2 mAbs at different phases of CIA. (a-b) Exacerbation of collagen-induced arthritis (CIA) by RMT2-14 treatment.
DBA/1 mice were immunized with primary type II collagen (CII)/complete Freund’s adjuvant (CFA) on day 0 and secondary CII/incomplete
Freund’s adjuvant (IFA) on day 21. Two groups of mice were treated with RMT2-14 or control IgG every three days from day 0 to day 42. (a)
Clinical score and (b) incidence of arthritis were evaluated from day 0. (c) Effect of anti-T cell immunoglobulin and mucin domain (TIM)-2
monoclonal antibodies (mAbs) at the early phase of CIA. Mice were immunized with CII/CFA once on day 0 and treated with RMT2-14, RMT2-25,
RMT2-26, or control IgG from day 0 to day 17. Clinical score of arthritis was evaluated from day 0. (d) Effect of anti-TIM-2 mAbs at the late phase
of CIA. Mice were immunized with CII/CFA once on day 0 and treated with RMT2-14, RMT2-25, RMT2-26, or control IgG from day 15 to day 32.
Clinical score of arthritis was evaluated from day 0. Results are presented as the mean ± standard error of the mean of 10 mice in each group.
*, P < 0.05 as compared with control IgG. Similar results were obtained in three independent experiments.
normal control IgG RMT2-14
Figure 3 Effect of anti-TIM-2 mAbs on histopathological arthritis. Hind paws from normal mice and control IgG- or RMT2-14-treated
collagen-induced arthritis (CIA) mice at day 45 were stained with H&E. Original magnification, × 4. Representatives in each group of 10 mice are
shown.
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ted mice and the control IgG-treated mice (P>0.05 at
every concentration of dCII).
To further evaluate in the effect of anti-TIM-2 mAbs
on the priming of antigen-specific CD4 T cells, DBA/1
mice were immunized with OVA/CFA and treated with
RMT2-14 or control IgG on days 0, 2, and 4. LN cells
were harvested on day 7, restimulated in vitro with var-
ious doses of OVA, and proliferative response and cyto-
kine production (IFN-g and IL-17) were assessed. As
shown in Figure 4b, neither proliferative response nor
cytokine production were affected by the RMT2-14
treatment as compared with the control IgG treatment
(P>0.05 at every concentration of dCII). IL-4 and IL-5
were measured but not detectable (data not shown).
Taken together, these results suggest that the anti-TIM-
2 mAbs treatment do not affect the development/induc-
tion of Th1 and Th17 cells, particularly the priming of
Th1 and Th17 responses.
Expression of TIM-2 on B cells but not CD4 T cells
We further examined the expression of TIM-2 on sple-
nic CD4 T cells by flow cytometric analysis using
RMT2-26. TIM-2 expression was not detected on
freshly isolated splenic CD4 T cells (data not shown).
To determine the expression of TIM-2 upon T cell
activation, splenic CD4 T cells were stimulated with
immobilized anti-CD3 mAb in the presence or absence
of soluble anti-CD28 mAb for 24 to 72 hours. As
s h o w ni nF i g u r e5 a ,T I M - 2e x p r e s s i o nw a sn o tf o u n d
on CD4 T cells even when stimulated with both anti-
CD3 and anti-CD28 mAbs. We also examined the
expression of TIM-2 on splenic B cells, but TIM-2
expression was not detected on freshly isolated splenic
B cells (data not shown). To determine the expression
of TIM-2 upon B cell activation, splenic B cells were
stimulated with combinations of anti-IgM, anti-CD40,
and recombinant IL-4 for 24 to 72 hours. As shown in
Figure 5b, the stimulation with anti-IgM + anti-CD40
or anti-CD40 mAb + IL-4 up-regulated TIM-2 expres-
sion on B cells. The combination of anti-IgM + anti-
CD40 + IL-4 markedly enhanced TIM-2 expression at
48 to 72 hours (Figure 5b). Similar results were
obtained when RMT2-14 or RMT2-25 were used for
staining (data not shown). Moreover, RMT2-25 and
RMT2-26 precipitated the approximately 55 kDa
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Page 7 of 12protein, which was also precipitated from TIM-2/
L5178Y cells, from B cells stimulated with anti-IgM +
anti-CD40 + IL-4 for 48 hours [See Figure S1b in
Additional file 1].
Effect of anti-TIM-2 mAbs treatment on CII-specific
antibody production
We next investigated the CII-specific IgG1, IgG2a, and
IgG2b Ab levels in the sera from the mice, which were
immunized with CII/CFA once and treated with anti-
TIM-2 mAbs or control IgG in the early phase. As
shown in Figure 6a, the serum levels of anti-CII IgG2a
(day 16; 0.017 ± 0.006 vs 0.086 ± 0.016 unit, control
IgG vs RMT2-14, n = 10, P < 0.001, day 24; 0.163 ±
0.033 vs 0.423 ± 0.084 unit, control IgG vs RMT2-14, n
=1 0 ,P = 0.004) and IgG2b (day 24; 0.257 ± 0.051 vs
0.444 ± 0.074 unit, control IgG vs RMT2-14, n =1 0 ,
P = 0.044) Abs were significantly increased in the
RMT2-14-treated mice as compared with the control-
IgG-treated mice. Similarly, the early-phase treatment
with RMT2-25 significantly enhanced anti-CII IgG1
(0.675 ± 0.133 vs 1.234 ± 0.16 unit, control IgG vs
RMT2-14, n =8 ,P = 0.031), IgG2a (0.853 ± 0.177 vs
1.533 ± 0.191 unit, control IgG vs RMT2-14, n =8 ,P =
0.035), and IgG2b (0.623 ± 0.117 vs 1.159 ± 0.214 unit,
control IgG vs RMT2-14, n =8 ,P = 0.049) Abs at day
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Page 8 of 1232 after immunization (Figure 6b). In contrast, RMT2-
26 treatment did not affect the CII-specific Ab produc-
tion (Figure 6b, n =8 ,P>0.8 each isotype). These results
raise the possibility that the exacerbation of CIA by
RMT2-14 and RMT2-25 resulted from the enhancement
of anti-CII Abs production.
Effect of anti-TIM-2 mAbs on B cell proliferation in vitro
Given the dynamic expression of TIM-2 on B cells, it
seems likely that TIM-2 regulates B cell activation or
function, and both RMT2-14 and RMT2-25 can block
or stimulate B cells by signaling through TIM-2. To
address this possibility, splenic B cells from DBA/1 mice
were stimulated with anti-IgM, anti-CD40, and IL-4 in
t h ep r e s e n c eo fa n t i - T I M - 2m A b so rc o n t r o lI g Gf o r
48 hours, and then the proliferative response was
assessed. As shown in Figure 7a, proliferation of anti-
IgM/anti-CD40/IL-4-stimulated B cells was not affected
by the addition of control IgG or RMT2-26 (10458.5 ±
725.6 vs 10507.3 ± 1063.7 cpm, control IgG vs RMT2-
26, P = 0.971). In contrast, the addition of RMT2-14
(10458.5 ± 725.6 vs 13008.3 ± 725.6 cpm, control IgG
vs RMT2-14, P = 0.025) and RMT2-25 (10458.5 ± 725.6
vs 13129.3 ± 418.4 cpm, control IgG vs RMT2-25, P =
0.019) significantly enhanced the proliferation. Similar
results were obtained when B cells were purified from
the spleen of BALB/c mice (Figure 7b; 9632.8 ± 293.6
control IgG, vs 10465.8 ± 911.3 RMT2-26, P =0 . 4 1 8 ,v s
13420 ± 615.5 RMT2-14, P <0.001, vs 13811.8 ± 459.3
RMT2-25, P < 0.001). To avoid positive or negative sig-
naling through FcgRs [15], B cells were purified from
FcRg-deficient mice and anti-CD16/32 mAb was added
into the culture. As shown in Figure 7c, proliferation of
anti-IgM/anti-CD40/IL-4-stimulated B cells not affected
by the addition of control IgG or RMT2-26 (6844.8 ±
272.7 vs 6861 ± 112 cpm, control IgG vs RMT2-26, P =
0.958). In contrast, the addition of RMT2-25 signifi-
cantly enhanced the proliferation (6844.8 ± 272.7 vs
8566.3 ± 616.2 cpm, control IgG vs RMT2-25, P =
0.43). The addition of RMT2-14 slightly enhanced the
proliferation, but not significant (6844.8 ± 272.7 vs
7459.5 ± 329.1 cpm, control IgG vs RMT2-14, P =0 . 2 ) .
In addition, the proliferation of B cells was also
enhanced by the addition of H-ferritin (Figure 7c, P <
0.01). Unexpectedly, the addition of RMT2-14 (8788 ±
160 vs 9907.5 ± 172.9 cpm, control IgG vs RMT2-14,
P = 0.003) or RMT2-25 (8788 ± 160 vs 11127.5 ± 664.6
cpm, control IgG vs RMT2-25, P = 0.014) further
enhanced the B cell proliferation rather than to block
the enhancement by H-ferritin. In contrast, RMT2-26
did not affect this (8788 ± 160 vs 9227.8 ± 595.9 cpm,
control IgG vs RMT2-26, P = 0.5). We further examined
that naive splenic B cells from DBA/1 mice were stimu-
lated with anti-IgM, anti-CD40, and IL-4 in the presence
of anti-TIM-2 mAbs or control IgG, and H-ferritin was
subsequently added to the culture after 24 hours. The
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Figure 7 Effect of anti-TIM-2 mAbs on B cell proliferation in vitro. Purified splenic B cells from (a) DBA/1, (b) BALB/c, or (c) FcRg-deficient
mice were stimulated with anti-IgM, anti-CD40, and IL-4 in the absence or presence of H-ferritin and indicated monoclonal antibodies (mAbs)
for 48 hours. Proliferative response was assessed by pulsing the cultures with 0.5 μCi/well
3H-thymidine for the last six hours. Data are expressed
as the mean ± standard error of the mean of triplicate wells. *, P < 0.05; **, P < 0.01 as compared with control IgG. The results are representative
of two experiments in each mouse strain. TIM, T cell immunoglobulin and mucin domain.
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Page 9 of 12addition of RMT2-14 and RMT2-25 significantly
enhanced the proliferation [See Additional file 4].
RMT2-14 and RMT2-25 enhances production of IgG2b and
IgG3 in vitro
We further examined whether anti-TIM-2 stimulation
on B cells influenced secretion of each Ig isotype. Puri-
fied splenic B cells were stimulated with anti-IgM, anti-
CD40, and IL-4 in the presence of anti-TIM-2 mAbs or
control rat IgG. Culture supernatants were harvested at
day 7 and subjected to a CBA assay for the seven mouse
Ig isotypes [16,17]. As shown in Figure 8, supernatants
from the RMT2-14 and RMT2-25 cultures showed
higher IgG2b/l and IgG3/ levels as compared with the
control IgG and RMT-2-26 cultures. Collectively, these
results suggest that the exacerbation of CIA by RMT2-
14 and RMT2-25 was caused by enhancement of B cell
activation and Ab production through agonistic stimula-
tion of TIM-2 on B cells by these mAbs.
Discussion
To explore the contribution of TIM-2 to the development
of CIA, we generated anti-mouse TIM-2 mAbs (RMT2-
14, RMT2-25, and RMT2-26), which bound to TIM-2
cDNA transfectants but not to those expressing the other
TIM family molecules (TIM-1 B6, TIM-1 BALB, TIM-3
B6, TIM-3 BALB, and TIM-4). All three mAbs precipi-
tated an approximately 55 kDa protein from TIM-2/
L5178Y cells, consistent with the molecular mass of TIM-
2 previously reported [6]. Moreover, all of these mAbs
inhibited the binding of H-ferritin to TIM-2 transfectants.
These results indicate that the anti-TIM-2 mAbs used in
this study are specific for mouse TIM-2 and can interrupt
the interaction between TIM-2 and H-ferritin. RMT2-14-
or RMT2-25-treated mice showed a substantially
enhanced development of CIA. Moreover, the
administration of RMT2-14 or RMT2-25 during the early
phase effectively exacerbated the disease severity, although
it was not effective during the late phase. In vitro restimu-
lation of draining LN cells showed that the anti-TIM-2
mAb treatment did not affect dCII-specific proliferative
response or production of Th1 and Th17 cytokines (IFN-g
and IL-17). These results suggest that TIM-2 dose not
play a major role in the development of Th1 or Th17 cells
during the early phase. In support of this theory, we also
found that the anti-TIM-2 mAb treatment did not inhibit
the priming of OVA-reactive Th1 and Th17 cells induced
by OVA/CFA immunization. On the other hand, it was
notable that the treatment with RMT2-14 or RMT2-25
enhanced the serum levels of anti-CII IgG1, IgG2a, and
IgG2b Abs. Moreover, RMT2-14 or RMT2-25 enhanced B
cell proliferation and Ig production in vitro. Collectively,
these results suggest that TIM-2 delivers a signal into B
cells, which enhances proliferation and Ab production and
that the exacerbation of CIA by RMT2-14 and RMT2-25
resulted from the enhancement of B cell activation and
function by agonistic effects of these mAbs.
Several recent studies have indicated that TIM-2 may
have inhibitory functions in Th2 immune responses.
TIM-2-Ig fusion protein induced T cell hyperprolifera-
tion and enhanced production of Th2 cytokines in vivo
[9]. A subsequent study also showed that TIM-2-Ig-trea-
ted or TIM-2-deficient mice showed exacerbated lung
inflammation in the OVA-induced asthma model [10].
These results suggested that TIM-2 could be involved in
the suppression of Th2-mediated immune responses.
TIM-2 was not expressed on CD4 T cells constitutively
but up-regulated following activation for Th2 condition
but not Th1 condition [9]. We show here that TIM-2
expression was not found on primary activated CD4
T cells and the anti-TIM-2 mAb treatment did not
affect Th1 and Th17 responses, suggesting that TIM-2
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or Th17 cells in CIA. Thus, the present enhancement of
arthritis severity by anti-TIM-2 mAbs does not result
from inhibition of Th2 response or an augmentation of
Th1 or Th17 response. However, a previous study has
indicated that the administration of TIM-2-Ig at the
induction phase or just before disease onset reduced the
severity of experimental autoimmune encephalomyelitis
(EAE), which is a Th17-mediated autoimmune disease
model [9]. The mechanism for such differential roles of
TIM-2 in EAE above and CIA is presently unknown. It
is possible that TIM-2 has some additional binding
molecule other than H-ferritin and Sema4A. TIM-2-Ig,
but not anti-TIM-2 mAbs, may interrupt the interaction
between TIM-2 and the unknown ligand or receptor.
Further studies are required to address this possibility.
A previous study by Chen et al. indicated that
Sema4A-Ig fusion protein does not bind to the TIM-2-
transfectants [4]. Consistent with this report, we have
been unable to confirm the binding of Sema4A and
TIM-2 (data not shown). On the other hand, we
observed that H-ferritin bound to mouse TIM-2-trans-
fected cells. A previous study has suggested that H-ferri-
tin can impair the maturation of B cells in vitro [18]. In
our present study, H-ferritin enhanced B cell prolifera-
tion induced by anti-IgM, anti-CD40, and IL-4. This
enhancement was not blocked by anti-TIM-2 mAbs,
whereas these mAbs could inhibit the binding of H-fer-
ritin to TIM-2 transfectants. Notably, RMT2-14 and
RMT2-25 did not inhibit H-ferritin binding to activated
B cells [See Additional file 5]. Therefore, some mole-
cules other than TIM-2 might be responsible for the
enhancement of B cell proliferation by H-ferritin. In any
case, H-ferritin-TIM-2 interaction might not contribute
to the development of CIA, because the administration
of RMT2-26, which could block the H-ferritin-TIM-2
interaction as efficiently as RMT2-25 and more effi-
ciently than RMT2-14, did not affect the development
of CIA.
It has been demonstrated that the TIM-2 is expressed
at low levels on splenic B cells and at higher levels on
germinal center B cells [4]. TIM-2 expression was mark-
edly up-regulated on splenic B cells by stimulation with
anti-IgM, anti-CD40, and IL-4 in vitro. RMT2-14 and
RMT2-25 enhanced B cell proliferation and Ig produc-
tion in vitro and anti-CII Ab production in vivo. B cells
receive multiple signals during their differentiation into
antibody-secreting cells. These include signals delivered
by antigen through the B-cell receptor that drive prolif-
eration, signals delivered by cytokines that initiate Ig
class switching, and signals through CD40 or Toll-like
receptors, which synergize with cytokine signals to cause
class-switch recombination and antibody secretion.
Class-switch recombination involves activation of the
gene for activation-induced cytidine deaminase, followed
by deletional switch recombination and expression of
mature transcripts of the switched Ig isotype [19-21]. To
confirm the contribution of TIM-2 signal to the induc-
tion of class-switch recombination, therefore, further
studies are required whether TIM-2 signaling can
induce activation of activation-induced cytidine
deaminase.
Conclusions
The administration of anti-TIM-2 mAbs exacerbated
CIA through enhancement of B cell activation and Ab
production during the early phase, but not induction of
Th1 or Th17 cells. Mouse TIM-2 and TIM-1 are highly
homologous, but it is unclear whether they have similar
functions. It has been suggested that mouse TIM-2 may
share some functions with human TIM-1 based on a
close sequence homology. We have observed that mouse
TIM-1 is also highly expressed on splenic B cells after
stimulation with anti-IgM, anti-CD40, and IL-4 in vitro
(unpublished observation). Therefore, it is possible that
human TIM-1 may contribute to B cell activation and
Ab production in rheumatoid arthritis patients, as
revealed for mouse TIM-2 in CIA mice.
Additional material
Additional file 1: Immunoprecipitation of TIM-2 antigen with anti-
TIM-2 mAbs. (a) T cell immunoglobulin and mucin domain (TIM)-2/
L5178Y or L5178Y cells (1 × 10
7) were lysed in a lysis buffer containing
0.5% Nonidet P-40, 50 mM Tris, and 250 mM NaCl. (b) Purified splenic B
cells (1 × 10
7) from DBA/1 mice were stimulated with anti-IgM, anti-
CD40, and IL-4 for 48 hours and lysed in the lysis buffer. The cleared
lysates were immunoprecipitated with RMT2-14-, RMT2-25-, RMT2-26-, rat
IgG2a-, or rat IgG2b-preloaded protein G-Sepharose. The beads were
washed with the lysis buffer, and bound proteins were eluted with 1%
SDS sample buffer, subjected to 10% SDS-PAGE under nonreducing
condition, and then blotted onto polyvinylidene difluoride membrane
(Millipore). The blotted proteins were detected using biotin-conjugated
RMT2-14, RMT2-25, RMT2-26, rat IgG2a, or rat IgG2b followed by avidin-
biotinylated peroxidase complex and SuperSignal West Dure Extended
Duration Substrate. The positions of molecular mass markers are
indicated at the right in kilodaltons.
Additional file 2: Competitive inhibition test. T cell immunoglobulin
and mucin domain (TIM)-2/L5178Y cells were pre-incubated with 10 μg
of RMT2-14, RMT2-25, RMT-2-26, or control rat IgG and then stained with
biotinylated RMT2-14 (0.5 μg), RMT2-25 (0.1 μg), or RMT-2-26 (0.1 μg)
followed by PE-labeled streptavidin to determine whether these
monoclonal antibodies (mAbs) recognized different TIM-2 antigen
epitopes. Thick lines indicate the staining with the respective mAb and
the dotted lines indicate background staining with control IgG.
Additional file 3: Effect of anti-TIM-2 mAb treatment on antigen-
specific T cell proliferation and cytokine production. DBA/1 mice
were immunized with type II collagen (CII)/complete Freund’s adjuvant
(CFA) on day 0 and treated with RMT2-14 or control IgG every three
days from day 0 to day 12. Draining lymph node (LN) cells from 10 mice
were isolated and pooled at day 14 and cultured with the indicated
concentrations of denatured CII (dCII). For estimating proliferation, 0.5 μCi
3H-thymidine was added during the last six hours of a 96-hour culture.
Production of IFN-g and IL-17 in the culture supernatants at 120 hour
was determined by ELISA. IL-4 and IL-5 were not detectable in the
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Page 11 of 12culture supernatants. Results are expressed as the mean ± standard
deviation.
Additional file 4: Effect of anti-TIM-2 mAbs on B cell proliferation in
vitro. Purified small resting splenic B cells from DBA/1 mice were
stimulated with anti-IgM, anti-CD40, and IL-4 in the presence of anti-T
cell immunoglobulin and mucin domain (TIM)-2 monoclonal antibodies
(mAbs) or control IgG, and H-ferritin was added to the culture after 24
hours. Proliferative response was assessed by pulsing the cultures with
0.5 μCi/well
3H-thymidine for the last six hours of 72 hours. Data are
expressed as the mean ± standard error of the mean of triplicate wells. *,
P < 0.05 as compared with control IgG.
Additional file 5: Anti-TIM-2 mAbs do not inhibit H-ferritin binding
to activated B cells. Purified splenic B cells were stimulated with the
combination of anti-IgM, anti-CD40 monoclonal antibody (mAb), and IL-4
for 72 hours. Cells were pre-incubated with 10 μg of RMT2-14, RMT2-25,
or control rat IgG and then stained with Alexa647-labeled H-ferritin. Thick
lines indicate the staining with Alexa647-labeled H-ferritin and the dotted
lines indicate background staining with PBS.
Abbreviations
Ab: antibody; BSA: bovine serum albumin; CBA: cytometric bead array; CFA:
complete Freund’s adjuvant; CIA: collagen-induced arthritis; CII: type II
collagen; dCII: denatured CII; ELISA: enzyme-linked immunosorbent assay; H-
ferritin: the heavy chain of ferritin; IFA: incomplete Freund’s adjuvant; IFN:
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ovalbumin; PBS: phosphate-buffered saline; RT-PCR: reverse transcription
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cell immunoglobulin and mucin domain.
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